Oncology Institute (NASDAQ:TOI) Major Shareholder Purchases $136,345.00 in Stock

The Oncology Institute, Inc. (NASDAQ:TOI) major shareholder Jorey Chernett bought 33,500 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $4.07 per share, for a total transaction of $136,345.00. Following the transaction, the insider directly owned 10,567,858 shares of the company’s stock, valued at approximately $43,011,182.06. This represents a 0.32% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Jorey Chernett also recently made the following trade(s):

• On Tuesday, May 19th, Jorey Chernett bought 5,000 shares of Oncology Institute stock. The stock was purchased at an average cost of $4.05 per share, with a total value of $20,250.00.
• On Tuesday, May 19th, Jorey Chernett purchased 30,000 shares of Oncology Institute stock. The shares were purchased at an average price of $4.09 per share, for a total transaction of $122,700.00.
• On Thursday, April 9th, Jorey Chernett purchased 20,000 shares of Oncology Institute stock. The shares were purchased at an average cost of $3.10 per share, for a total transaction of $62,000.00.
• On Tuesday, March 24th, Jorey Chernett purchased 125,000 shares of Oncology Institute stock. The shares were purchased at an average cost of $3.11 per share, for a total transaction of $388,750.00.
• On Friday, March 20th, Jorey Chernett purchased 25,000 shares of Oncology Institute stock. The shares were purchased at an average cost of $3.35 per share, for a total transaction of $83,750.00.
• On Tuesday, March 17th, Jorey Chernett acquired 75,000 shares of Oncology Institute stock. The stock was purchased at an average cost of $3.42 per share, with a total value of $256,500.00.
• On Monday, March 16th, Jorey Chernett bought 60,985 shares of Oncology Institute stock. The shares were acquired at an average price of $3.29 per share, for a total transaction of $200,640.65.
• On Friday, March 13th, Jorey Chernett bought 263,000 shares of Oncology Institute stock. The shares were acquired at an average price of $2.92 per share, for a total transaction of $767,960.00.

Oncology Institute Trading Up 2.7%

Shares of TOI opened at $4.59 on Friday. The firm has a market cap of $453.68 million, a PE ratio of -12.41 and a beta of 0.33. The company’s 50 day simple moving average is $3.50 and its 200-day simple moving average is $3.33. The Oncology Institute, Inc. has a 12-month low of $2.02 and a 12-month high of $4.88.

Oncology Institute (NASDAQ:TOI) last announced its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The business had revenue of $147.44 million for the quarter, compared to analysts’ expectations of $142.10 million. As a group, equities research analysts forecast that The Oncology Institute, Inc. will post -0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Oncology Institute

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. LPL Financial LLC grew its holdings in shares of Oncology Institute by 1.5% during the fourth quarter. LPL Financial LLC now owns 270,885 shares of the company’s stock worth $964,000 after buying an additional 3,900 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Oncology Institute by 9.1% in the 4th quarter. AQR Capital Management LLC now owns 48,072 shares of the company’s stock valued at $171,000 after purchasing an additional 4,007 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Oncology Institute by 5.5% in the 4th quarter. HighTower Advisors LLC now owns 85,851 shares of the company’s stock valued at $306,000 after purchasing an additional 4,489 shares in the last quarter. Cetera Investment Advisers boosted its holdings in Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after purchasing an additional 4,545 shares in the last quarter. Finally, R Squared Ltd boosted its holdings in Oncology Institute by 42.7% in the 1st quarter. R Squared Ltd now owns 16,353 shares of the company’s stock valued at $50,000 after purchasing an additional 4,891 shares in the last quarter. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. BTIG Research reissued a “buy” rating and set a $7.00 price target on shares of Oncology Institute in a report on Monday, March 9th. Needham & Company LLC reissued a “buy” rating and set a $5.00 price target on shares of Oncology Institute in a report on Monday, March 9th. B. Riley Financial raised their price target on Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oncology Institute in a report on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Oncology Institute has a consensus rating of “Moderate Buy” and an average price target of $7.00.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.